{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:25:13Z","timestamp":1794605113298,"version":"4.9.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T-cell therapies are highly effective for multiple myeloma (MM) but their impressive efficacy is associated with treatment-related neurotoxicities in some patients. In CARTITUDE-1, 5% of patients with MM reported movement and neurocognitive treatment-emergent adverse events (MNTs) with ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen-targeted CAR T-cell therapy. We assessed the associated factors for MNTs in CARTITUDE-1. Based on common features, patients who experienced MNTs were characterized by the presence of a combination of at least two variables: high tumor burden, grade \u22652 cytokine release syndrome (CRS) or any grade immune effector cell-associated neurotoxicity syndrome (ICANS) after cilta-cel infusion, and high CAR T-cell expansion\/persistence. Strategies were implemented across the cilta-cel development program to monitor and manage patients with MNTs, including enhanced bridging therapy to reduce baseline tumor burden, early aggressive treatment of CRS and ICANS, handwriting assessments for early symptom detection, and extended monitoring\/reporting time for neurotoxicity beyond 100 days post-infusion. After successful implementation of these strategies, the incidence of MNTs was reduced from 5% to &lt;1% across the cilta-cel program, supporting its favorable benefit\u2013risk profile for treatment of MM.<\/jats:p>","DOI":"10.1038\/s41408-022-00629-1","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T06:02:48Z","timestamp":1645682568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":305,"title":["Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-3843","authenticated-orcid":false,"given":"Adam D.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca D.","family":"Santomasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2969-0116","authenticated-orcid":false,"given":"Jaime","family":"G\u00e1llego P\u00e9rez-Larraya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Arnulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoletta","family":"Lendvai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn C.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7354-1244","authenticated-orcid":false,"given":"Kevin C.","family":"De Braganca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Schecter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreta","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8728-7627","authenticated-orcid":false,"given":"Erin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Cornax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Zudaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunsi","family":"Olyslager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepu","family":"Madduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Varsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lida","family":"Pacaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Akram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2597-6822","authenticated-orcid":false,"given":"Andrzej","family":"Jakubowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-0819","authenticated-orcid":false,"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,24]]},"reference":[{"key":"629_CR1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"629_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"629_CR3","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331\u201342.","journal-title":"N Engl J Med"},{"key":"629_CR4","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"629_CR5","unstructured":"FDA Adverse event reporting system public dashboard. 2020. https:\/\/fis.fda.gov."},{"key":"629_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"key":"629_CR7","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8:958\u201371.","journal-title":"Cancer Discov"},{"key":"629_CR8","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726\u201337.","journal-title":"N Engl J Med"},{"key":"629_CR9","unstructured":"Kymriah. Prescribing information. Novartis Pharmaceuticals Corporation; 2021."},{"key":"629_CR10","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7:1404\u201319.","journal-title":"Cancer Discov"},{"key":"629_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"629_CR12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 2021;398:314\u201324.","journal-title":"Lancet"},{"issue":"15_suppl","key":"629_CR13","doi-asserted-by":"publisher","first-page":"8005","DOI":"10.1200\/JCO.2021.39.15_suppl.8005","volume":"39","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Berdeja JG, Madduri D, Jakubowiak AJ, Agha ME, Cohen AD. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed\/refractory multiple myeloma (R\/R MM): Updated results from CARTITUDE-1. J Clin Oncol. 2021;39(15_suppl):8005","journal-title":"J Clin Oncol"},{"key":"629_CR14","unstructured":"Yescarta. Prescribing information. Kite Pharma; 2021."},{"key":"629_CR15","unstructured":"Tecartus. Prescribing information. Kite Pharma; 2021."},{"key":"629_CR16","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011;117:4691\u20135.","journal-title":"Blood"},{"key":"629_CR17","doi-asserted-by":"publisher","first-page":"S433","DOI":"10.1016\/S2666-6367(21)00560-1","volume":"27","author":"H Einsele","year":"2021","unstructured":"Einsele H, van de Donk NWCJ, Arnulf B, Schecter JM, De Braganca KC, Varsos H, et al. CARTITUDE-2: Phase 2 multicohort study of ciltacabtagene autoleucel, a B-cell maturation antigen\u2013directed chimeric antigen receptor T-cell therapy, in patients with multiple myeloma. Transpl Cell Ther. 2021;27:S433\u201342021.","journal-title":"Transpl Cell Ther"},{"key":"629_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl J Med. 2018;378:439\u201348.","journal-title":"N. Engl J Med"},{"key":"629_CR19","doi-asserted-by":"publisher","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","volume":"38","author":"S Mailankody","year":"2020","unstructured":"Mailankody S, Jakubowiak AJ, Htut M, Costa LJ, Lee K, Ganguly S, et al. Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): update of the phase 1\/2 EVOLVE study (NCT03430011). J Clin Oncol. 2020;38:8504. 15_suppl","journal-title":"J Clin Oncol"},{"key":"629_CR20","unstructured":"ABECMA. Prescribing information. Celgene Corporation, a Bristol-Myers Squibb Company; 2021."},{"issue":"Suppl 1","key":"629_CR21","first-page":"26","volume":"136","author":"Y Lin","year":"2020","unstructured":"Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D. et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: updated results from phase 1 CRB-401 study. Blood . 2020;136(Suppl 1):26\u201327.","journal-title":"Blood"},{"key":"629_CR22","doi-asserted-by":"crossref","unstructured":"Marella M, Yao X, Carreira V, Bustamante MF, Clark HB, Jackson CC, et al. Comprehensive BCMA expression profiling in adult normal human brain suggests a low risk of on-target neurotoxicity in BCMA-targeting multiple myeloma therapy. J Histochem Cytochem. 2022 [in press].","DOI":"10.1369\/00221554221079579"},{"key":"629_CR23","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Investig. 2019;129:2210\u201321.","journal-title":"J Clin Investig"},{"issue":"Suppl 1","key":"629_CR24","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1182\/blood-2018-99-113548","volume":"132","author":"S Mailankody","year":"2018","unstructured":"Mailankody S, Htut M, Lee KP, Bensinger W, Devries T, Piasecki J. et al. JCARH125, anti-BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma: Initial proof of concept results from a phase 1\/2 multicenter study (EVOLVE). Blood . 2018;132(Suppl 1):957","journal-title":"Blood"},{"key":"629_CR25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25502","volume":"86","author":"J Gust","year":"2019","unstructured":"Gust J, Finney OC, Li D, Brakke HM, Hicks RM, Futrell RB, et al. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann Neurol. 2019;86:42\u201354.","journal-title":"Ann Neurol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00629-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00629-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00629-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T20:06:42Z","timestamp":1700251602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00629-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["629"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00629-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,24]]},"assertion":[{"value":"15 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AC served in a consulting or advisory role for AstraZeneca, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Genentech\/Roche, Janssen, and Takeda, and received patents, royalties, and other intellectual property from Novartis. SJ is a consultant for Bristol Myers Squibb, Janssen, Karyopharm Therapeutics, Merck, Sanofi, and Takeda Pharmaceuticals. SP is supported by the National Cancer Institute (NCI) (R01 CA244899, CA252222) and receives research funding from Amgen, Bristol Myers Squibb, and Karyopharm. BS is an inventor on United States Provisional Patent Application No.: US20210181179A1 \u201cDiagnosis and treatment of immunotherapy-induced neurotoxicity\u201d filed by Memorial Sloan Kettering Cancer Center, served in a consulting or advisory role for Celgene, Janssen, Legend Biotech, Incyte, and In8bio, and received research funding from ADC Therapeutics. JGP-L served in a consulting or advisory role for Janssen, served in speakers bureau for Eisai, and received research funding from DNAtrix. NWCJvdD received grant support and advisory board fees from Bristol-Myers Squibb\/Celgene, Janssen, Novartis, and Amgen, advisory board fees from Takeda, Servier, Bayer, Adaptive Biotechnologies, Roche, GlaxoSmithKline, and Sanofi, and grant support from Cellectis. BA served in a consulting or advisory role for Amgen, Celgene, and Janssen-Cilag, received travel expenses from Amgen, Celgene, Janssen-Cilag, Sanofi, and Takeda, received honoraria from Celgene, Janssen-Cilag, Sanofi, and Takeda, and received research funding from Janssen-Cilag. M-VM received consulting fees from Janssen-Cilag, GlaxoSmithKline, Celgene, Amgen, Regeneron, Pfizer, AbbVie, Takeda, Roche\/Genentech, Sanofi, Oncopeptides, and Adaptive Biotechnologies. DM, KCDB, JMS, HV, LM, EL, IC, NL, YO, EZ, and CL are employees of Janssen. CCJ is an employee of Janssen and a consultant physician at the Memorial Sloan Kettering Cancer Center (New York, NY, USA). LP, MA, and DG are employees of Legend Biotech. AJ served in a consulting or advisory role for and received honoraria from AbbVie, Amgen, Bristol-Myers Squibb\/Celgene, GlaxoSmithKline, Janssen, Juno Therapeutics, Karyopharm Therapeutics, and Sanofi. HE served in a consulting or advisory role for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, and Takeda, received travel expenses from Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda, received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, and Takeda, and received research funding from Amgen, Bristol-Myers Squibb, Celgene, and Janssen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}